Navigation Links
SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193

iruses are classified as Category A pathogens by the Centers for Disease Control and Prevention (CDC) due to the great risk that they pose to public health and national safety. Lassa fever is both a current world health threat, as it is prevalent in parts of West Africa (the CDC reports estimates of as many as 300,000 new cases each year), and a bioterror threat, due to its previous history as an object of weaponization research. Signs and symptoms of Lassa fever typically occur 1-3 weeks after the patient comes into contact with the virus. These include fever, retrosternal pain (pain behind the chest wall), sore throat, back pain, cough, abdominal pain, vomiting, diarrhea, conjunctivitis, facial swelling, proteinuria (protein in the urine), and mucosal bleeding. Neurological problems have also been described, including hearing loss, tremors, and encephalitis.

The Implementation Plan for Chemical, Biological, Radiological, and Nuclear Threats released in April by the Department of Health and Human Services lists arenaviruses as one of the biologic threats for which they plan to purchase medical countermeasures.

Dr. Eric A. Rose, Chairman and Chief Executive Officer of SIGA, adds, "Progress on our Lassa fever virus drug demonstrates the robustness of our product pipeline and furthers our goal to develop safe and effective countermeasures against all of the Category A viral pathogens."

Development of this Lassa antiviral is supported by the National Institutes of Health (NIH), which awarded SIGA a $6.0 million grant in September 2006.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA is a leading company in the discovery of pharmaceutical agents to fight emerging pathogens. SIGA
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Senate Passes Drug-Safety Reforms to Prevent Future Vioxx-type Disasters; House Urged to Act on Strong Drug Safety Bill
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
5. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
6. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
7. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
8. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
9. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
10. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
11. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: SIGA Passes First Hurdle with Lassa Fever Antiviral
(Date:6/3/2015)... , June 3, 2015 aTyr Pharma, Inc. ... discovery and development of Physiocrine-based therapeutics to address rare diseases, ... Annual William Blair Growth Stock Conference to be held at ... , June 9-11, 2015. John Mendlein , ... presentation on the Company at 9:20 a.m. CT on Wednesday, ...
(Date:6/3/2015)... 3, 2015  GenVec, Inc. (NASDAQ: GNVC ) ... T. Curiel and his team from the School ... Louis (WUSTL).  Dr. Curiel is the director ... Division within the Department of Radiation Oncology. ... will create modified versions of GenVec,s gorilla adenovectors that ...
(Date:6/3/2015)... June 3, 2015  EIP Pharma LLC ( www.eippharma.com ... clinical development of VX-745 in Alzheimer,s disease (AD) is ... and potent inhibitor of the alpha isoform of the ... alpha). "Recent human genetic data demonstrate that ... with symptomatic Alzheimer,s, while the science also indicates the ...
Breaking Medicine Technology:GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 2GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 3GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 4EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 2EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 3
... Telik, Inc. (Nasdaq: TELK ) today reported ...  The net loss for the quarter ended March 31, 2011 was $3.7 ... of $5.3 million, or $0.10 per share, for the same period ... in the first quarter of 2011 were $1.7 million, compared to ...
... WOONSOCKET, R.I., May 16, 2011 Obtaining prior authorization ... patients and pharmacists that currently requires phone calls, faxes ... available, they do not provide both a real-time solution ... electronic health record (EHR) tools.  Recognizing this gap in ...
Cached Medicine Technology:Telik Announces First Quarter 2011 Financial Results 2Telik Announces First Quarter 2011 Financial Results 3CVS Caremark to Pilot Electronic Prior Authorization to Help Speed Patient Access to Prescription Medication 2CVS Caremark to Pilot Electronic Prior Authorization to Help Speed Patient Access to Prescription Medication 3
(Date:6/3/2015)... 2015 DailyEndorphin is pleased to announce ... With this highly configurable new offering, DE's annual ... many components of its wellness programming for the entire ... , With this new module, annual clients may also ... Create participant surveys, (3) Continually report on participant progress ...
(Date:6/3/2015)... Foot and Ankle Specialists of the ... ( Clarksville Division ) was recently presented with the ... Wound Care (SAWC) and the American Podiatric Medical Association ... The Conference was held on April 29-May 3, 2015, ... Antonio, TX. , Dr. Casey Friske graduated from ...
(Date:6/3/2015)... evigilo, a world leader in delivering and developing ... by launching a new and enhanced content-centric website: ... logo depicting a sun-like image with a color movement ... Know. To Act. In time. The color palate, it ... borderless approach to alerting and delivering safety and sense ...
(Date:6/2/2015)... Concorde Career Colleges, Inc., announced today ... Bell will manage day-to-day operations for the privately held ... the opportunity to help our Concorde team deliver on ... Concorde in part due to reports like Beyond College ... in Memphis and Portland.” , Bell brings 14 years ...
(Date:6/2/2015)... On March 19th, 2015, LiveToBeSober.org held an ... of Legends at Detroit’s Ford Field. Hosted by former ... the goal of the conference was to raise awareness ... the benefits of effective professional rehabilitation programs. It also ... that are available to them in regards to the ...
Breaking Medicine News(10 mins):Health News:DailyEndorphin Launches Wellness "Events" Portal 2Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Receives Award at the Spring 2015 Symposium of Advanced Wound Care Conference 2Health News:Keep calm! evigilos' "sun" will come out tomorrow – to know, to act, in time. 2Health News:Concorde Career Colleges Announces New President and COO 2Health News:Rehabilitation Facility Graduate Shares Her Story at "Fighting Addiction Together" Conference 2
... A Boston University School of Medicine-led research team has ... Stem (iPS) cells, derived from mouse fibroblasts, by using ... the reprogramming process. The result is a powerful laboratory ... embryonic stem cell-like cells for clinical purposes such as ...
... the spinal column called the multifidus muscle may in fact ... to researchers at the University of California, San Diego School ... role of this poorly understood muscle has been published on ... Journal of Bone and Joint Surgery . , "The ...
... MORRIS PLAINS, N.J., Jan. 7 Immunomedics, Inc. ... focused on developing monoclonal antibodies to treat cancer and ... President and Chief Executive Officer, will be presenting at ... held in San Francisco, CA.Ms. Sullivan,s presentation, which is ...
... save on ice skating admission PHILADELPHIA, Jan. 7 ... families to attend this year,s Healthy Kids Fest on Sunday, ... Landing, from 1 p.m. to 5 p.m. Just in time ... fitness will feature music and free activities for the whole ...
... CKD Care and Your Practice Culture: Improve Your ... Association 2009 Annual Meeting, "CKD and Your ... in Baltimore, will include plenary sessions and interactive ... to today,s nephrology practitioners. RPA will convene ...
... Inc.,(NYSE: HI ) has appointed Jan ... on continuous improvement and operational excellence initiatives,across the ... team, reporting directly to President and CEO Kenneth ... recently serving as vice president of operations in ...
Cached Medicine News:Health News:Converting adult somatic cells to pluripotent stem cells using a single virus 2Health News:Unique skeletal muscle design contributes to spine stability 2Health News:Immunomedics to Present at 27th Annual J.P. Morgan Healthcare Conference 2Health News:Immunomedics to Present at 27th Annual J.P. Morgan Healthcare Conference 3Health News:Families Encouraged to Enjoy Healthy Kids Fest at the Blue Cross RiverRink January 11 2Health News:Renal Physicians Association 2009 Annual Meeting 2Health News:Hillenbrand, Inc. Appoints Jan Santerre Vice President of Lean Business 2
... The Vision5L Digital ... 5- or 7-lead, ... a signal preview,screen. ... using a compact,flash ...
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
... CSV-1000CVA test face is used to evaluate both ... levels (high, 25% and 12.5%) of LogMAR acuity ... face as well as the two spatial frequencies ... most widely used for cataract documentation because eye ...
... is used widely for screening refractive surgery ... from 20/10 to 20/100 and one row ... ,The patient can be easily screened in ... contrast sensitivity. If a contrast sensitivity deficit ...
Medicine Products: